Use of NPSP558 in the Treatment of Hypoparathyroidism
Public ClinicalTrials.gov record NCT00732615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.
Study identification
- NCT ID
- NCT00732615
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2008
- Primary completion
- Sep 27, 2011
- Completion
- Sep 27, 2011
- Last update posted
- Jun 2, 2021
2008 – 2011
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic-Scottsdale | Scottsdale | Arizona | 85259 | — |
| Advance Medical Research LLC | Lakewood | California | 90712 | — |
| Diabetes Associates | Orange | California | 92868 | — |
| University of California-San Francisco VA Medical Center | San Francisco | California | 94127 | — |
| Palm Springs Research Institute | Hialeah | Florida | 33012 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Michigan Bone and Mineral Clinic PC | Detroit | Michigan | 48236 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University Physicians Group | Staten Island | New York | 10301 | — |
| Physicians East | Greenville | North Carolina | 27834 | — |
| University of Cincinnati Bone Health and Osteoporosis Center | Cincinnati | Ohio | 45219 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Cetero Research DGD Research Inc. | San Antonio | Texas | 78229 | — |
| Hillcrest Family Health Center | Waco | Texas | 76708 | — |
| The Vancouver Clinic | Vancouver | Washington | 98664 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
Recently updated Hypoparathyroidism trials
Other public records listing Hypoparathyroidism. Sorted by last update posted; newest first. Not a recommendation.
- NCT07699471: A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism Recruiting
- NCT07083557: Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) Recruiting
- NCT07081997: A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism Recruiting
- NCT07264634: A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) Recruiting
- NCT07345494: A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding Recruiting
- NCT06961071: Parathyroid Allotransplant for Treatment of Hypoparathyroidism Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00732615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2021 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00732615 live on ClinicalTrials.gov.